Cure8 research brief
Why This Matters
Patients with multiple biologic failures appear more likely to have inflammatory comorbidities (including IBD) and to experience worse dermatology-related quality of life despite similar early skin improvement. That could affect monitoring and care planning.
Who Should Pay Attention
Clinicians managing psoriasis, researchers studying biologic treatment resistance, and adult patients with psoriasis—especially those with multiple prior biologic therapies or known inflammatory comorbidities.
Study Snapshot
What To Know
The study used a single-centre retrospective design and identified 50 of 545 patients as having multiple biologic failure. Associations were observed between MBF and inflammatory comorbidity, multimorbidity, and lower rates of optimal dermatology quality-of-life (DLQI 0/1) at weeks 12–16, while PASI90 skin responses were similar.
The IBD association was based on a small number of patients (n=12) and the authors describe it as hypothesis-generating. The findings may reflect biological refractoriness, treatment-pathway complexity (treatment sequencing, interruptions, or access issues), or both; the study design cannot fully separate these possibilities.
If you live with psoriasis and have multiple treatment failures, these results highlight the importance of evaluating comorbid inflammatory conditions and discussing quality-of-life concerns with your care team.
Keep In Mind
This is a single-centre, retrospective cohort reported as an abstract-level/full-text preprint on Research Square; the IBD association was based on only 12 patients and is hypothesis-generating. The study cannot prove causation or fully separate biological resistance from treatment-pathway factors.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.